NCT03416530 - ONC201 in Pediatric H3 K27M Gliomas | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

January 25, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

May 24, 2023

Conditions

Diffuse Intrinsic Pontine GliomaGlioma, Malignant

Interventions

DRUG

Dordaviprone (ONC201)

Dordaviprone is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.

Trial Locations (8)

10016

New York University, New York

30322

Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta

33176

Miami Cancer Institute, Miami

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48109

University of Michigan Cancer Center, Ann Arbor

77030

MD Anderson Cancer Center, Houston

94158

UCSF, Benioff Children's Hospital, San Francisco

98105

Seattle Children's Hospital, Seattle